These therapeutic effects of the TDP-43-targeting ASOs were observed even 4–6 months post injection on various disease phenotypes, including anxiety-like behavior and abnormal locomotor functions (Figure 3, Figure 4 and 4). Here, TARDBP is linked to Anxiety.